MATHEMATICAL MODEL OF IMMUNOTHERAPY RESPONSE TO ANTIBODIES AS A TREATMENT FOR CANCER

被引:0
|
作者
Simbawa, Eman [1 ]
Alharbi, Sara [1 ]
Aljohani, Jawaher [1 ]
Abosamra, Hala [1 ]
Aboushoushah, Samia [2 ]
Cristini, Vittorio [3 ]
机构
[1] King Abdulaziz Univ, Dept Math, Fac Sci, Jeddah 21589, Saudi Arabia
[2] King Abdulaziz Univ, Phys Dept, Fac Sci, Jeddah 21589, Saudi Arabia
[3] Houston Methodist Res Inst, Math Med Program, Houston, TX 77030 USA
关键词
antibodies; cancer; drug delivery; immunotherapy; mathematical modeling; MONOCLONAL-ANTIBODIES; THERAPY;
D O I
10.28919/cmbn/4570
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
Immunotherapy is a significant cancer treatment as it uses the body's natural immune system to fight cancer. To help boost the immune system, monoclonal antibodies (MABs) are used as they bind to cancer cells helping the immune system recognize these cells. In this paper, we present a mathematical model of nonlinear partial differential equations describing the interaction between the immune cells, MABs, and cancer cells. After nondimensionalizing the model, we analyzed the long-term behavior and found later that it is consistent with the numerical results. Then, we calculated the numerical solutions of the model with different values of the parameters (relative growth rate of cancer cells and the number of immune cells that are removed after killing a cancer cell) to determine the values that help increase the effectiveness of the treatment. We have considered the continuous delivery of antibodies over a certain period of time. These simulations showed that immune cells will eradicate cancer if the number of immune cells that are removed after killing a cancer cell is less than one. However, if each immune cell kills only one cancer cell, then the treatment reduces the cancer to a steady state or almost a steady state. On the other hand, if the relative growth rate of cancer cells is very small and each cancer cell needs more than one immune cell to kill it, then again, we get a steady state for cancer. However, if the relative growth rate is not small, then the cancer will grow after an initial decrease. This study could be implemented into a clinical trial with different delivery protocols of the drug to improve cancer treatment.
引用
收藏
页码:1 / 13
页数:13
相关论文
共 50 条
  • [31] Bispecific antibodies in cancer immunotherapy
    Chen, Siqi
    Li, Jing
    Li, Qing
    Wang, Zhong
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (10) : 2491 - 2500
  • [32] Tumor Clearance Analysis on a Cancer Chemo-Immunotherapy Mathematical Model
    Paul A. Valle
    Luis N. Coria
    Yolocuauhtli Salazar
    Bulletin of Mathematical Biology, 2019, 81 : 4144 - 4173
  • [33] Tumor Clearance Analysis on a Cancer Chemo-Immunotherapy Mathematical Model
    Valle, Paul A.
    Coria, Luis N.
    Salazar, Yolocuauhtli
    BULLETIN OF MATHEMATICAL BIOLOGY, 2019, 81 (10) : 4144 - 4173
  • [34] A numerical study of a mathematical model of pulsed immunotherapy for superficial bladder cancer
    Wei, Hsiu-Chuan
    JAPAN JOURNAL OF INDUSTRIAL AND APPLIED MATHEMATICS, 2013, 30 (02) : 441 - 452
  • [35] Trispecific antibodies for cancer immunotherapy
    Yao, Yin
    Hu, Yiyin
    Wang, Fei
    IMMUNOLOGY, 2023, 169 (04) : 389 - 399
  • [36] Monoclonal antibodies for cancer immunotherapy
    Weiner, Louis M.
    Dhodapkar, Madhov V.
    Ferrone, Soldano
    LANCET, 2009, 373 (9668): : 1033 - 1040
  • [37] Chemical antibodies for cancer immunotherapy
    Evbuomwan, Moses O.
    Maeda, Yoshiko
    Kumaresan, Pappanaicken
    Lam, Kit S.
    CANCER RESEARCH, 2010, 70
  • [38] Monoclonal antibodies in cancer immunotherapy
    Kimiz-Gebologlu, Ilgin
    Gulce-Iz, Sultan
    Biray-Avci, Cigir
    MOLECULAR BIOLOGY REPORTS, 2018, 45 (06) : 2935 - 2940
  • [39] A numerical study of a mathematical model of pulsed immunotherapy for superficial bladder cancer
    Hsiu-Chuan Wei
    Japan Journal of Industrial and Applied Mathematics, 2013, 30 : 441 - 452
  • [40] Active immunotherapy with monoclonal antibodies as a therapeutic option for the treatment of pancreatic cancer
    Barquero-Solano, Arisai
    Guevara-Saborio, Gloriana
    Montero-Rivera, Jeison
    Vargas-Sandoval, Lazaro
    Velasquez-Alfaro, Luis Daniel
    Mora-Roman, Juan Jose
    TECNOLOGIA EN MARCHA, 2022, 35 (03): : 16 - 34